Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- efficacy of intravitreal aflibercept injection of 2.0mg aflibercept
研究概览
简要总结
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
详细描述
This is an open-label, randomized, one-year, multiple-dose study of 2mg aflibercept in patients with PCV.
The study consists of the baseline visit on day 0 and a mandatory clinic visit every 30 days to assess efficacy and safety. All patients will receive three monthly injections of 2mg intravitreal aflibercept injection followed by treatment every 60 days through 720 days (24 months). Patients can be treated every 30 days if needed.
The fellow eye may be treated with intravitreal aflibercept injection per the investigator's discretion at any point during the study if evidence of disease activity are met: exudation or hemorrhage secondary to polypoidal choroidal vasculopathy or exudative AMD. The fellow eye will not be considered the study eye. If treatment with aflibercept is to be given in the fellow eye, the injections are to be administered according to the Food and Drug Administration (FDA) approved label for EYLEA®.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age > 25 years of age.
- •In the opinion of the principal investigator, the study eye has PCV with active exudation and/or bleeding that may benefit from treatment with study medication.
- •Diagnosis of PCV via ICG Angiography with evidence of active leakage, active bleeding or recent decreased in vision.
- •Baseline visual acuity better than or equal to 20/200 using ETDRS
- •Willing and able to comply with clinic visits and study-related procedures
- •Provide signed informed consent
排除标准
- •Any history of previous vitrectomy
- •Previous cataract surgery within the preceding 2 months of Day 0
- •Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- •Presence of any condition that would jeopardize the patient's participation in this study
- •Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry
- •For the Treatment-Naïve cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis, Eylea) in the study eye
- •For the Previous-Treated cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days or enrollment in this study
- •For the Previous-Treated cohort: no prior Eylea in the study eye
- •Known allergy to any component of the study drug
- •Blood pressure >180/119 (systolic above 180 or diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the patient can be eligible.
- •Major surgery within 28 days prior to randomization or major surgery planned within the next 12 months. Major surgery is defined as a surgical procedure that is more extensive than needle biopsy/aspiration placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter
- •Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months prior to randomization
- •Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization
- •Pregnant or breast-feeding women
- •Simultaneous participation in another medical investigational trial
- •Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)
研究组 & 干预措施
Previously Treated
Patients that have previously received treatment for polypoidal choroidal vasculopathy.
Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm.
干预措施: Intravitreal aflibercept injection 2.0mg (Drug)
Treatment-Naive
Patients that have not received treatment for polypoidal choroidal vasculopathy.
Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm.
干预措施: Intravitreal aflibercept injection 2.0mg (Drug)
结局指标
主要结局
efficacy of intravitreal aflibercept injection of 2.0mg aflibercept
时间窗: 2 Years
This study will evaluate the efficacy of intravitreal aflibercept injection of 2.0mg aflibercept administered Q8W following an initial loading dose of 3 monthly injections in patients with polypoidal choroidal vasculopathy with active exudation or bleeding as measured by: • Mean change in BCVA between Day 0 (Baseline) and Day 720 (M24)
次要结局
- Proportion of Patients with Stable, Improved, Significant Improved, Decreased, Significant Decreased Vision(6 Months, 12 Months, 18 Months, 24 Months)
- Proportion of Patients with decrease in Subretinal Hemorrhage and/or Exudates(Month 6, Month 12, Month 18, Month 24)
- Proportion of patients with decreased / complete resolution of Polypoidal Polyp.(Month 3, Month 6, Month 12, Month 18, Month 24)
- Mean Change in Choroidal Thickness(Baseline, Month 6, Month 12, Month 18, Month 24)
- Proportion of subject with a decrease or complete resolution of branching vascular network from PCV(Month 3, Month 6, Month 12, Month 18, Month 24)
- Determine mean change in Central Foveal Thickness and/or peripapillary edema as measured by SD-OCT(Baseline, Month 6, Month 12, Month 18, Month 24)
- Proportion of previously treated and treatment naive patients that require additional dosing outside of the protocol determined dosing schedule(Month 24)
- Assess changes on Autofluorescence(Baseline, Month 6, Month 12, Month 18, Month 24)
- Incidence and Severity of Ocular and Non-Ocular Adverse Events(Baseline through Month 24)
研究者
Gregg T. Kokame, MD
Primary Investigator
Hawaii Pacific Health